Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SAF2012-39852-C02-02

Financiado

INTERACCION SIRTUINA 1-AMPK-MTOR EN LOS PROCESOS DE FRAGILIDAD MITOCONDRIAL COMO...

INTERACCION SIRTUINA 1-AMPK-MTOR EN LOS PROCESOS DE FRAGILIDAD MITOCONDRIAL COMO DIANA PARA LA PREVENCION DE LA NEURODEGENERACION: IMPLICACION EN LA ENFERMEDAD DE ALZHEIMER THE INTERPLAY BETWEEN SIRTUIN 1 AND AMPK IS RELEVANT BECAUSE THESE TWO MOLECULES ARE THE TWO KEY ENERGY SENSOR SYSTEMS THAT REGULATE CELL SURVIVAL, PROLIFERATION AND SENESCENCE. IT HAS BEEN PROPOSED THAT THE ANTI-AGEING ACTIVITY O... ver más

01/01/2012

CSIC

105K€

Presupuesto del proyecto: 105K€

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Financiación concedida El organismo AGENCIA ESTATAL DE INVESTIGACIÓN notifico la concesión del proyecto el día 2012-01-01 No tenemos la información de la convocatoria

0% 100%

Participantes

CSIC

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-39852-C02-01 INTERACCION SIRTUINA1-AMPK-MTOR EN LOS PROCESOS DE FRAGILIDA... 94K€ Cerrado

PID2019-104214RB-I00 HOMEOSTASIS MITOCONDRIAL Y ACTIVACION GENICA DURANTE EL ESTR... 121K€ Cerrado

PID2021-122239OB-I00 SEÑALIZACION POR CA2+: UNA NUEVA DIANA PARA ACTUAR SOBRE EL... 191K€ Cerrado

PCIN-2016-095 EJE MITOCONDRIA-TYROSINA KINASA COMO DIANA PARA PREVENIR EL... 140K€ Cerrado

BFU2016-77634-R INTEGRACION DE LA SEÑALIZACION CELULAR CON EL METABOLISMO MI... 109K€ Cerrado

SAF2009-13093-C02-02 MODULACION DE SIRTUINA1 COMO TERAPIA PREVENTIVA EN EL ENVEJE... 182K€ Cerrado

Líder del proyecto

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 552M€

Presupuesto del proyecto 105K€

Descripción del proyecto THE INTERPLAY BETWEEN SIRTUIN 1 AND AMPK IS RELEVANT BECAUSE THESE TWO MOLECULES ARE THE TWO KEY ENERGY SENSOR SYSTEMS THAT REGULATE CELL SURVIVAL, PROLIFERATION AND SENESCENCE. IT HAS BEEN PROPOSED THAT THE ANTI-AGEING ACTIVITY OF SIRTUIN 1 IS A RESULT, IN PART, OF THE FINE-TUNING OF THE AMPK PATHWAY WHICH PREVENTS THE TRANSITION OF AN ORIGINAL PRO-SURVIVAL PROGRAM INTO A PRO-AGEING MECHANISM RESULTING IN SYSTEMIC DEGENERATION. THE PROCESS IS ELEGANTLY CONTROLLED BY A COMPLEX NETWORK INVOLVING MANY SIGNALING PROTEINS (AMPK, MTOR) AND BY THE RATIOS BETWEEN LOW-MOLECULAR-WEIGHT METABOLITES (E.G. NAD/NADH AND AMP/ATP). FINAL EFFECTOR MECHANISMS REGULATE MANY PRO-SURVIVAL PROCESSES, SUCH AS MITOCHONDRIAL BIOGENESIS AND AUTOPHAGY. IN CONCLUSION, ENERGY METABOLISM AND METABOLIC REGULATORS PLAY PIVOTAL ROLES IN CONTROLLING LONGEVITY AND CELLULAR SENESCENCE; HOWEVER THE PARTICIPATION AND SPECIFIC WEIGHT ON THESE PROCESSES ARE POORLY UNDERSTOOD IN THE CENTRAL NERVOUS SYSTEM, AND THE BENEFITS OF PHARMACOLOGICAL MODULATION OF SOME OF THESE PATHWAYS REMAIN UNCLEAR. HERE WE PROPOSE TO EXAMINE THE MECHANISMS OF NORMAL AND DISEASE-ASSOCIATED AGEING IN AN IN VIVO CONTEXT (SAMP8 AND 3XTG-AD MOUSE STRAINS), WITH THE AIM OF IDENTIFYING THE GENETIC AND BIOCHEMICAL CHANGE THAT MAY BE RELEVANT IN THE DEVELOPMENT OF DELETERIOUS PROCESSES THAT LEAD TO FRAILTY IN AGEING AND THEIR RELATIONSHIP WITH ALZHEIMER'S DISEASE (AD). RELEVANT ASPECTS AND MECHANISMS WILL BE ANALYZED FOR THEIR POTENTIAL TO TRIGGER AD-RELATED PATHOLOGY. TO THIS END, WE WILL USE AN ESTABLISHED MODEL OF SENESCENCE SAMP8 MICE, AN AD MOUSE MODEL (3XTG-AD) AND WE WILL DESIGN A CONTINUOUS PARADIGM MODEL SYSTEM OF INCREASED MITOCHONDRIAL FRAILTY: CONTROL MICE (SAMR1 AND NONTG (WILD TYPE FOR 3XTG-AD)); SAMR1 SUBJECTED TO A HIGH-FAT DIET; SENESCENCE-ACCELERATED MICE (SAMP8); SAMP8 SUBJECTED TO A HIGH-FAT DIET; AND TRANSGENIC AD MICE (3XTG-AD). THE MAIN OBJECTIVE WILL BE TO STUDY THE SIRTUIN 1-AMPK-MTOR PATHWAYS IN THE MOUSE MODELS OF CONTINUOUS AND PROGRESSIVE SENESCENCE AND AD, AND TO ESTABLISH THEIR PARTICIPATION IN THE MITOCHONDRIAL DYSFUNCTION THAT LEADS TO FRAILTY. TO RESCUE FRAIL MITOCHONDRIA WE WILL MODULATE THE SIRTUIN 1-AMPK-MTOR NETWORK USING PHARMACOLOGICAL TREATMENTS (RESVERATROL, MELATONIN AND OTHER SPECIFIC AGENTS) AND GENETIC TOOLS THAT INDUCE CHANGES IN SIRTUIN 1 EXPRESSION. WE WILL ALSO ANALYZE THE SIRTUIN 1-AMPK-MTOR PATHWAYS AND MARKERS OF MITOCHONDRIAL FUNCTION IN HUMAN TISSUE FROM VARIOUS STAGES OF AGEING AND IN AD PATIENTS (CONTROL SUBJECTS, SENILE SUBJECTS SHOWING AMYLOID PATHOLOGY, SUBJECTS DIAGNOSED AT EARLY STAGES OF BRAAK AND BRAAK WITH TAU PATHOLOGY AND THOSE WITH OVERT AD PATHOLOGY OF AMYLOID AND TAU). FINALLY, WE WILL ESTABLISH A CORRELATION BETWEEN WHOLE DATA FROM EXPERIMENTAL ANIMAL MODELS AND HUMAN TISSUE IN ORDER TO IDENTIFY NEW TARGETS FOR POTENTIAL THERAPEUTIC INTERVENTIONS AGAINST PATHOLOGICAL AGEING AND AD DEVELOPMENT.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores